Ángela Pedraza

Ángela Pedraza

Auto-generated profile, based on publicly available information

Ángela Pedraza

Hospital Universitario Clínica San Rafael, Bogotá, Colombia.

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2018 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
OMOlga Morales-Múnera
Olga Morales-Múnera
ÁPÁngela Pedraza
Ángela Pedraza
LNLaura Niño-Serna
Laura Niño-Serna
Background: Omalizumab efficacy and safety in children older than 6 years has been clearly demonstrated in controlled clinical trials, but only in few real-life studies.Objective: To assess the response with omalizumab addition in children with moderate to severe persistent asthma in real-life conditions.Method: Observational study with a 12-month real-life follow-up in a group of 61 children older than 6 years who were assessed for asthma control before treatment was started and at 4 and 12 months.Results: After 12 months of treatment with omalizumab, there was symptom improvement both for those younger and older than 12 years (p = 0.001). There was a decrease in controller drug consumption in 73% of patients; in 61%, inhaled corticosteroid dose was reduced, and 8% discontinued its use. Inhaled corticosteroid average dose was decreased to 396 ± 298 µg, with this being statistically significant (p = 0.02).Conclusion: Omalizumab is an efficacious, safe and well-tolerated drug as add-on therapy for clinical control of moderate and severe allergic asthma that has not improved with standard therapies.

27 December 2018 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
ÁPÁngela Pedraza
Ángela Pedraza
MVMaría Isabel Vargas-Rumilla
María Isabel Vargas-Rumilla
JRJuan Leandro Ramírez-Roa
Juan Leandro Ramírez-Roa
Background: Primary immunodeficiencies are inherited diseases that compromise numerous systems and whose clinical manifestation is varied. It is an underdiagnosed pathology in Colombia.Objectives: To characterize primary immunodeficiencies in patients younger than 16 years who attended the San Rafael Clinical University Hospital, Bogota, between January 1, 2010 and July 1, 2016, as well as to provide information that enriches local, national and international statistics.Methods: Observational study of a cases series. All patients diagnosed with primary immunodeficiencies were analyzed, with a total of 75 patients.Results: Patients between one and five years of age (33 % of all cases) were the most affected, followed by patients from six to 11 months, including 17 cases; 21 cases corresponded to patients under 1 year of age; 80 % of affected children were males. Antibody deficiency was the most common type of immunodeficiency (56 %), followed by T/B lymphocyte deficiency (38 %).Conclusions: Patients with primary immunodeficiencies of the analyzed hospital had the same age and gender distribution observed in international studies. The most common primary immunodeficiency was due to antibody defects.